FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3118577092> ?p ?o ?g. }

• W3118577092 endingPage "862" @default.
• W3118577092 startingPage "851" @default.
• W3118577092 abstract "Abstract Purpose Patients with HER2-positive metastatic breast cancer (MBC) usually receive many years of trastuzumab treatment. It is unknown whether these patients require continuous left ventricular ejection fraction (LVEF) monitoring. We studied a real-world cohort to identify risk factors for cardiotoxicity to select patients in whom LVEF monitoring could be omitted. Methods We included patients with HER2-positive MBC who received > 1 cycle of trastuzumab-based therapy in eight Dutch hospitals between 2000 and 2014. Cardiotoxicity was defined as LVEF < 50% that declined > 10%-points and was categorized into non-severe cardiotoxicity (LVEF 40–50%) and severe cardiotoxicity (LVEF < 40%). Multivariable Cox and mixed model analyses were performed to identify risk factors associated with cardiotoxicity. Additionally, we explored the reversibility of cardiotoxicity in patients who continued trastuzumab. Results In total, 429 patients were included. Median follow-up for cardiotoxicity was 15 months (interquartile range 8–31 months). The yearly incidence of non-severe + severe cardiotoxicity in the first and second year was 11.7% and 9.1%, respectively, which decreased thereafter. The yearly incidence of severe cardiotoxicity was low (2.8%) and stable over time. In non-smoking patients with baseline LVEF > 60% and no cardiotoxicity during prior neoadjuvant/adjuvant treatment, the cumulative incidence of severe cardiotoxicity was 3.1% after 4 years of trastuzumab. Despite continuing trastuzumab, LVEF decline was reversible in 56% of patients with non-severe cardiotoxicity and in 33% with severe cardiotoxicity. Conclusions Serial cardiac monitoring can be safely omitted in non-smoking patients with baseline LVEF > 60% and without cardiotoxicity during prior neoadjuvant/adjuvant treatment." @default.
• W3118577092 created "2021-01-18" @default.
• W3118577092 creator A5004217461 @default.
• W3118577092 creator A5017612284 @default.
• W3118577092 creator A5019680927 @default.
• W3118577092 creator A5024709204 @default.
• W3118577092 creator A5033272927 @default.
• W3118577092 creator A5034350317 @default.
• W3118577092 creator A5043853734 @default.
• W3118577092 creator A5047672077 @default.
• W3118577092 creator A5048535376 @default.
• W3118577092 creator A5052326351 @default.
• W3118577092 creator A5055583849 @default.
• W3118577092 creator A5055588115 @default.
• W3118577092 creator A5064453966 @default.
• W3118577092 creator A5073385013 @default.
• W3118577092 creator A5075041827 @default.
• W3118577092 creator A5079739250 @default.
• W3118577092 date "2021-01-04" @default.
• W3118577092 modified "2023-10-01" @default.
• W3118577092 title "Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?" @default.
• W3118577092 cites W1980019455 @default.
• W3118577092 cites W2020268094 @default.
• W3118577092 cites W2068483637 @default.
• W3118577092 cites W2086578266 @default.
• W3118577092 cites W2098787760 @default.
• W3118577092 cites W2099545363 @default.
• W3118577092 cites W2100224620 @default.
• W3118577092 cites W2137228442 @default.
• W3118577092 cites W2146384083 @default.
• W3118577092 cites W2149908785 @default.
• W3118577092 cites W2163168145 @default.
• W3118577092 cites W2166199281 @default.
• W3118577092 cites W2178685240 @default.
• W3118577092 cites W2298838354 @default.
• W3118577092 cites W2318605753 @default.
• W3118577092 cites W2546933023 @default.
• W3118577092 cites W2558002415 @default.
• W3118577092 cites W2560560709 @default.
• W3118577092 cites W2592769823 @default.
• W3118577092 cites W2768267412 @default.
• W3118577092 cites W2800400752 @default.
• W3118577092 cites W2890579914 @default.
• W3118577092 cites W2921447286 @default.
• W3118577092 cites W2948656647 @default.
• W3118577092 cites W2971394750 @default.
• W3118577092 cites W2999536665 @default.
• W3118577092 cites W3032800311 @default.
• W3118577092 cites W4252714226 @default.
• W3118577092 doi "https://doi.org/10.1007/s10549-020-06039-w" @default.
• W3118577092 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8019427" @default.
• W3118577092 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33394273" @default.
• W3118577092 hasPublicationYear "2021" @default.
• W3118577092 type Work @default.
• W3118577092 sameAs 3118577092 @default.
• W3118577092 citedByCount "11" @default.
• W3118577092 countsByYear W31185770922021 @default.
• W3118577092 countsByYear W31185770922022 @default.
• W3118577092 countsByYear W31185770922023 @default.
• W3118577092 crossrefType "journal-article" @default.
• W3118577092 hasAuthorship W3118577092A5004217461 @default.
• W3118577092 hasAuthorship W3118577092A5017612284 @default.
• W3118577092 hasAuthorship W3118577092A5019680927 @default.
• W3118577092 hasAuthorship W3118577092A5024709204 @default.
• W3118577092 hasAuthorship W3118577092A5033272927 @default.
• W3118577092 hasAuthorship W3118577092A5034350317 @default.
• W3118577092 hasAuthorship W3118577092A5043853734 @default.
• W3118577092 hasAuthorship W3118577092A5047672077 @default.
• W3118577092 hasAuthorship W3118577092A5048535376 @default.
• W3118577092 hasAuthorship W3118577092A5052326351 @default.
• W3118577092 hasAuthorship W3118577092A5055583849 @default.
• W3118577092 hasAuthorship W3118577092A5055588115 @default.
• W3118577092 hasAuthorship W3118577092A5064453966 @default.
• W3118577092 hasAuthorship W3118577092A5073385013 @default.
• W3118577092 hasAuthorship W3118577092A5075041827 @default.
• W3118577092 hasAuthorship W3118577092A5079739250 @default.
• W3118577092 hasBestOaLocation W31185770921 @default.
• W3118577092 hasConcept C119060515 @default.
• W3118577092 hasConcept C120665830 @default.
• W3118577092 hasConcept C121332964 @default.
• W3118577092 hasConcept C121608353 @default.
• W3118577092 hasConcept C126322002 @default.
• W3118577092 hasConcept C143998085 @default.
• W3118577092 hasConcept C164705383 @default.
• W3118577092 hasConcept C2776694085 @default.
• W3118577092 hasConcept C2778198053 @default.
• W3118577092 hasConcept C2778233292 @default.
• W3118577092 hasConcept C2779786085 @default.
• W3118577092 hasConcept C530470458 @default.
• W3118577092 hasConcept C61511704 @default.
• W3118577092 hasConcept C71924100 @default.
• W3118577092 hasConcept C72563966 @default.
• W3118577092 hasConcept C78085059 @default.
• W3118577092 hasConcept C88879693 @default.
• W3118577092 hasConceptScore W3118577092C119060515 @default.
• W3118577092 hasConceptScore W3118577092C120665830 @default.
• W3118577092 hasConceptScore W3118577092C121332964 @default.
• W3118577092 hasConceptScore W3118577092C121608353 @default.

• next